Retatrutide hits 28% weight loss in Phase 3 A summary of the interesting content that I consumed this past week What I Read This Week: a summary of the content that I consumed this past week Caught My Eye 1) Retatrutide hits 28% weight loss in Phase 3 On May 21, Eli Lilly released Phase 3 results for retatrutide from the 2,339-patient TRIUMPH-1 obesity trial
Current guidelines recommend that anyone who may benefit from obesity treatment including people using GLP-1 medications should have access to comprehensive support for healthy weight management (4)
Whilst preliminary studies suggest these medications may reduce drinking in some individuals, the evidence remains limited and inconclusive
Whether marketed as an all-natural supplement or prescribed by a physician, both supplements and pharmaceuticals present benefits and risksespecially since some of these formulas clearly modulate GLP-1 in a similar manneralbeit to a much lesser extentthan drugs like Ozempic do
The total weight of the lyophilized powder may be slightly more due to the presence of small amounts of mannitol or other cryoprotectants used to form a stable cake
The initial dose is 10 mcg once daily subcutaneously for 14 days, on the 15 th day the dose is increased to 20 mcg once daily subcutaneously